This report provides the full collection of musculoskeletal disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
Trends in musculoskeletal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Musculoskeletal partnering agreement structure
Musculoskeletal partnering contract documents
Top musculoskeletal deals by value
Most active musculoskeletal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive musculoskeletal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering musculoskeletal deals.
The report presents financial deal terms values for musculoskeletal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
The report is intended to provide the reader with an in-depth understanding and access to musculoskeletal trends and structure of deals entered into by leading companies worldwide.
Global Musculoskeletal Partnering 2016 to 2023 includes:
Trends in musculoskeletal dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of musculoskeletal deal contract documents
Comprehensive access to over 600 musculoskeletal deal records
The leading musculoskeletal deals by value since 2016
Most active musculoskeletal dealmakers since 2016
The report includes deals for the following indications: Arthritis, Ankylosing spondylitis, Juvenile arthritis, Osteoarthritis, Psoriatic arthritis, Rheumatoid arthritis, Bone fracture, Hip, Carpel tunnel syndrome, Frozen shoulder, Gout, Knee, Meniscus damage, Muscular dystrophy, Osteoporosis, Paget's disease, Spinal muscular atrophy, Bone pain, Back pain, Muscular pain, Stiffness, Weakness, plus other musculoskeletal indications.
In Global Musculoskeletal Partnering 2016 to 2023, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Musculoskeletal Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 600 musculoskeletal deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in musculoskeletal dealmaking 2.1. Introduction 2.2. Musculoskeletal partnering over the years 2.3. Musculoskeletal partnering by deal type 2.4. Musculoskeletal partnering by industry sector 2.5. Musculoskeletal partnering by stage of development 2.6. Musculoskeletal partnering by technology type 2.7. Musculoskeletal partnering by therapeutic indication
Chapter 4 - Leading musculoskeletal deals and dealmakers 4.1. Introduction 4.2. Most active in musculoskeletal partnering 4.3. List of most active dealmakers in musculoskeletal 4.4. Top musculoskeletal deals by value
Chapter 5 - Musculoskeletal contract document directory 5.1. Introduction 5.2. Musculoskeletal partnering deals where contract document available
Chapter 6 - Musculoskeletal dealmaking by therapeutic target 6.1. Introduction 6.2. Deals by musculoskeletal therapeutic target
Companies Mentioned
3D-Side
3SBio
A2A Pharmaceuticals
Aavis Pharmaceuticals
Abarca
Abbvie
AbCellera
AC Bioscience
Accenture
Actigraph
Activbody
Active Implants
Adaptive Health
Additive Orthopaedics
Advanced Human Imaging
AdventHealth
Affinia Therapeutics
AGC Asahi Glass
AgNovos Healthcare
AgomAb Therapeutics
Akashi Therapeutics
AKL Research and Development
AlfaMed
Aligos Therapeutics
AliMed
Alkem Laboratories
Allergan
AlloSource
Almirall
Alpine Immune Sciences
Altamira Bio
Altasciences
Alvogen
Alvotech
Ambry Genetics
Amedica
Amend Surgical
American Association of Neuromuscular & Electrodiagnostic Medicine
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
